Sunshine Lake Pharma: Olorigliflozin Capsules Added to China’s 2026 National Reimbursement Drug List

Bulletin Express11-15

Sunshine Lake Pharma Co., Ltd. (Sunshine Lake Pharma, 06887) announced that its Class 1 innovative drug Olorigliflozin Capsules (brand: Dong Ze’an) have been accepted into the National Catalogue of Drugs for Basic Medical Insurance, Maternity Insurance and Work-related Injury Insurance (2026 NRDL). Reimbursement coverage will commence on 1 January 2027.

Olorigliflozin is a sodium–glucose cotransporter-2 inhibitor with proprietary intellectual property rights. Cleared for marketing by China’s National Medical Products Administration in January 2026, the therapy targets glycaemic control in adults with type 2 diabetes mellitus, both as monotherapy and in combination with metformin. Two multicentre, randomised, double-blind Phase III trials showed that 24-week treatment significantly lowered HbA1c as well as fasting and post-prandial blood glucose, with benefits sustained through 52 weeks. Additional advantages included reductions in blood pressure and body weight, while safety was comparable to placebo.

The NRDL inclusion strengthens Sunshine Lake Pharma’s comprehensive diabetes portfolio. The group already markets seven insulin products—Recombinant Human Insulin, Insulin Glargine, Insulin Aspart, Insulin Aspart 30, Mixed Protamine Human Insulin 30R, Insulin Degludec, and Insulin Degludec/Insulin Aspart. Pipeline assets feature HEC-151, an ultra-long-acting weekly insulin now in Phase I trials, positioning the company for a multi-tiered regimen spanning daily, weekly and combination formulations.

Internationally, the company’s self-developed Insulin Glargine Injection received U.S. FDA approval in April 2026, becoming the fourth such product authorised in the United States and marking Sunshine Lake Pharma as the first PRC pharmaceutical firm to commercialise insulin glargine in that market. The group is progressing registration efforts for additional insulin candidates, including Insulin Aspart and Insulin Degludec, to expand global reach and market share.

The forthcoming reimbursement status of Olorigliflozin, combined with a diversified insulin portfolio and advancing international approvals, positions Sunshine Lake Pharma to enhance its competitiveness in the growing diabetes treatment arena.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment